文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

人源化嵌合CALR癌蛋白造血表达小鼠模型可体内评估抗CALR免疫治疗

Hematopoietic expression of a chimeric murine-human CALR oncoprotein allows the assessment of anti-CALR antibody immunotherapies in vivo.
PubMed 文献 · Am J Hematol · 2021-05-03

该研究构建了条件性表达人突变CALR(del52)的转基因小鼠模型,小鼠出现类似原发性血小板增多症的表型,包括显著血小板增多和巨核细胞增多,并随年龄出现脾大和贫血。疾病可移植,突变CALR干细胞具有增殖优势,转录组显示致癌和炎症基因特征。抗人突变CALR单克隆抗体治疗可降低突变小鼠的血小板和干细胞计数,且突变CALR分泌不构成显著抗体陷阱。

要点

  • 人突变CALR del52转基因小鼠重现了CALR突变MPN的关键表型。
  • 突变CALR干细胞较野生型具有增殖优势,疾病可移植。
  • 抗人突变CALR抗体可降低小鼠血小板和干细胞计数。

核心结论

  • 该转基因小鼠模型重现了人CALR突变MPN,并可用于体内评估靶向人突变CALR表位的免疫治疗策略。

研究设计与样本

  • 研究采用小鼠内源性Calr位点条件性表达人突变外显子9(del52)的转基因小鼠模型。

主要发现

  • 小鼠出现类似原发性血小板增多症表型,表现为显著血小板增多和巨核细胞增多。
  • 疾病随年龄加重,出现明显脾大和贫血。
  • 疾病可移植,突变CALR干细胞较野生型干细胞显示增殖优势。
  • 造血干细胞转录组分析显示致癌和炎症基因表达特征。
  • 抗人突变CALR单克隆抗体治疗降低了突变小鼠的血小板和干细胞计数,且突变CALR分泌未构成显著抗体陷阱。

临床怎么用

  • 该模型可用于临床前评估靶向人突变CALR的免疫治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myeloproliferative neoplasms (MPNs) are characterized by a pathologic expansion of myeloid lineages. Mutations in JAK2, CALR and MPL genes are known to be three prominent MPN disease drivers. Mutant CALR (mutCALR) is an oncoprotein that interacts with and activates the thrombopoietin receptor (MPL) and represents an attractive target for targeted therapy of CALR mutated MPN. We generated a transgenic murine model with conditional expression of the human mutant exon 9 (del52) from the murine endogenous Calr locus. These mice develop essential thrombocythemia like phenotype with marked thrombocytosis and megakaryocytosis. The disease exacerbates with age showing prominent signs of splenomegaly and anemia. The disease is transplantable and mutCALR stem cells show proliferative advantage when compared to wild type stem cells. Transcriptome profiling of hematopoietic stem cells revealed oncogenic and inflammatory gene expression signatures. To demonstrate the applicability of the transgenic animals for immunotherapy, we treated mice with monoclonal antibody raised against the human mutCALR. The antibody treatment lowered platelet and stem cell counts in mutant mice. Secretion of mutCALR did not constitute a significant antibody sink. This animal model not only recapitulates human MPN but also serves as a relevant model for testing immunotherapeutic strategies targeting epitopes of the human mutCALR.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Achyutuni S, Nivarthi H, Majoros A, et al. Hematopoietic expression of a chimeric murine-human CALR oncoprotein allows the assessment of anti-CALR antibody immunotherapies in vivo. Am J Hematol. 2021. PMID: 33761144. doi:10.1002/ajh.26171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。